Regentis Biomaterials (RGNT) CFO discloses multi-year stock option grant

Rhea-AI Filing Summary

REGENTIS BIOMATERIALS LTD. Chief Financial Officer Gon Ori reported an initial holding of employee stock options. These options allow the purchase of 84,951 shares of common stock at an exercise price of $4.0000 per share and expire on February 23, 2037.

The option was granted on February 23, 2026 and vests over three years, with one-sixth vesting six months after the grant date and the remainder vesting quarterly, subject to continuous employment through each vesting date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gon Ori

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	02/23/2037	Common Stock	84,951	$4	D

Explanation of Responses:

1. This option was granted on February 23, 2026. The options shall vest on a quarterly basis, with one-sixth (1/6) of the options vesting upon the six-month anniversary of the grant date and one-twelfth (1/12) vesting on the last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date.

	/s/ Ori Gon	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did RGNT CFO Gon Ori report in this Form 3 filing?

Gon Ori reported an initial holding of employee stock options. These options relate to 84,951 shares of Regentis Biomaterials common stock, providing the right to buy shares at a fixed exercise price, subject to vesting and expiration terms described in the grant.

How many Regentis Biomaterials (RGNT) shares are covered by the CFO’s options?

The employee stock option grant covers 84,951 underlying shares of common stock. This represents the number of shares that may be purchased if all options vest and are exercised according to the vesting schedule and other conditions attached to the award.

What is the exercise price of the RGNT CFO’s stock options?

The options have an exercise price of $4.0000 per share. This is the fixed price at which Gon Ori may purchase Regentis Biomaterials common stock upon exercise of vested options, regardless of the market price at the time of exercise.

When do the Regentis Biomaterials (RGNT) CFO stock options expire?

The options expire on February 23, 2037. After this expiration date, any unexercised portion of the grant can no longer be exercised, even if the options were fully vested prior to that time under the award’s vesting schedule.

How do the RGNT CFO’s stock options vest over time?

One-sixth of the options vest on the six-month anniversary of the February 23, 2026 grant date. Thereafter, one-twelfth vests on the last day of each three-month period, contingent on continuous employment, until full vesting on the third anniversary.

Is the RGNT CFO’s option vesting dependent on continued employment?

Yes. Vesting is conditioned on the reporting person’s continuous employment through each vesting date. If employment ends before a given vesting date, the unvested portion tied to that date and subsequent dates generally would not become exercisable under the grant terms.